Paper39792181
Endoglin as a predictive biomarker for pemetrexed sensitivity in non-small-cell lung cancer: a cellular study.
Cheng CY and 7 others. Cancer Chemother Pharmacol, 2025. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Endoglin as a predictive biomarker for pemetrexed sensitivity in non-small-cell lung cancer: a cellular study. Papers, record 39792181. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39792181
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Endoglin as a predictive biomarker for pemetrexed sensitivity in non-small-cell lung cancer: a cellular study.
- PubMed
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Pemetrexed | Major topic |
| Carcinoma, Non-Small-Cell Lung | Major topic |
| Lung Neoplasms | Major topic |
| Endoglin | Major topic |
| Biomarkers, Tumor | Major topic |
| Cell Movement | Major topic |
| Humans | |
| Cell Line, Tumor | |
| Drug Resistance, Neoplasm | |
| Antineoplastic Agents | |
| A549 Cells | |
| Cell Proliferation | |
| Cell Cycle |
Source PubMed
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| CSH-2021-C-031 | Chung Shan Medical University Hospital | PubMed | ||
| MOST 111-2314-B-040-131 | Taiwan National Science and Technology Council | PubMed | ||
| MOST 111-2320-B-040-018-MY3 | Taiwan National Science and Technology Council | PubMed | ||
| 097-CCH-CSMU-04 | Changhua Christian Hospital | PubMed |
Source PubMed
References28
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 38754467 | Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology | J Natl Compr Canc Netw | 2024 | https://conductscience.org/library/papers/38754467 | PubMed |
| 2 | 17308042 | Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. | Mol Cancer Ther | 2007 | https://conductscience.org/library/papers/17308042 | PubMed |
| 3 | 29682186 | Novel drug-resistance mechanisms of pemetrexed-treated non-small cell lung cancer. | Oncotarget | 2018 | https://conductscience.org/library/papers/29682186 | PubMed |
| 4 | 20559153 | Genetic determinants of pemetrexed responsiveness and nonresponsiveness in non-small cell lung cancer cells. | J Thorac Oncol | 2010 | https://conductscience.org/library/papers/20559153 | PubMed |
| 5 | 27270426 | The ERK-ZEB1 pathway mediates epithelial-mesenchymal transition in pemetrexed resistant lung cancer cells with suppression by vinca alkaloids. | Oncogene | 2017 | https://conductscience.org/library/papers/27270426 | PubMed |
| 6 | 11164421 | Endoglin, a TGF-beta receptor-associated protein, is expressed by smooth muscle cells in human atherosclerotic plaques. | Atherosclerosis | 2000 | https://conductscience.org/library/papers/11164421 | PubMed |
| 7 | 15806144 | Characterization of murine S-endoglin isoform and its effects on tumor development. | Oncogene | 2005 | https://conductscience.org/library/papers/15806144 | PubMed |
| 8 | 18303046 | L- and S-endoglin differentially modulate TGFbeta1 signaling mediated by ALK1 and ALK5 in L6E9 myoblasts. | J Cell Sci | 2008 | https://conductscience.org/library/papers/18303046 | PubMed |
| 9 | 21737653 | Endoglin (CD105): a review of its role in angiogenesis and tumor diagnosis, progression and therapy. | Anticancer Res | 2011 | https://conductscience.org/library/papers/21737653 | PubMed |
| 10 | 31897911 | Continuous endoglin (CD105) overexpression disrupts angiogenesis and facilitates tumor cell metastasis. | Angiogenesis | 2020 | https://conductscience.org/library/papers/31897911 | PubMed |
| 11 | 34587660 | Preoperative plasma level of endoglin as a predictor for disease outcomes after radical cystectomy for nonmetastatic urothelial carcinoma of the bladder. | Mol Carcinog | 2022 | https://conductscience.org/library/papers/34587660 | PubMed |
| 12 | 35664553 | Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance). | Neurooncol Adv | 2022 | https://conductscience.org/library/papers/35664553 | PubMed |
| 13 | 20981476 | Endoglin suppresses human prostate cancer metastasis. | Clin Exp Metastasis | 2011 | https://conductscience.org/library/papers/20981476 | PubMed |
| 14 | 21042283 | Endoglin expression in breast tumor cells suppresses invasion and metastasis and correlates with improved clinical outcome. | Oncogene | 2011 | https://conductscience.org/library/papers/21042283 | PubMed |
| 15 | 19736306 | Endoglin phosphorylation by ALK2 contributes to the regulation of prostate cancer cell migration. | Carcinogenesis | 2010 | https://conductscience.org/library/papers/19736306 | PubMed |
| 16 | 17496924 | Endoglin inhibits prostate cancer motility via activation of the ALK2-Smad1 pathway. | Oncogene | 2007 | https://conductscience.org/library/papers/17496924 | PubMed |
| 17 | 26325105 | Identification of Endoglin as an epigenetically regulated tumour-suppressor gene in lung cancer. | Br J Cancer | 2015 | https://conductscience.org/library/papers/26325105 | PubMed |
| 18 | 35221721 | Plasma Endoglin is Associated with Favorable Outcome for Pemetrexed-Based Therapy in Advanced Non-Small Cell Lung Cancer. | Cancer Manag Res | 2021 | https://conductscience.org/library/papers/35221721 | PubMed |
| 19 | 21575631 | Sustained activation of ERK and Cdk2/cyclin-A signaling pathway by pemetrexed leading to S-phase arrest and apoptosis in human non-small cell lung cancer A549 cells. | Eur J Pharmacol | 2011 | https://conductscience.org/library/papers/21575631 | PubMed |
| 20 | 27156098 | Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage. | DNA Repair (Amst) | 2016 | https://conductscience.org/library/papers/27156098 | PubMed |
Genes5
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CCNA2 | 890 | PubTator's text mining | https://conductscience.org/library/genes/890 | NCBI Gene |
| CDK2 | 1017 | PubTator's text mining | https://conductscience.org/library/genes/1017 | NCBI Gene |
| CDKN1A | 1026 | PubTator's text mining | https://conductscience.org/library/genes/1026 | NCBI Gene |
| ENG | 2022 | PubTator's text mining | https://conductscience.org/library/genes/2022 | NCBI Gene |
| TP53 | 7157 | PubTator's text mining | https://conductscience.org/library/genes/7157 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39792181
GET https://conductscience.org/api/papers/v1/39792181/references?page=2